Skip to main content

Advertisement

SpringerLink
Log in

Ampulla of Vater Adenocarcinoma in a BRCA2 Germline Mutation Carrier

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

CT:

Computed tomography

PET:

Positron emission tomography

EUS:

Endoscopic ultrasound

IHC:

Immunohistochemistry

PARP:

Poly-ADP ribose polymerase

References

  1. Romiti A, Barucca V, Zullo A, Sarcina I, Di Rocco R, et al. Tumors of ampulla of Vater: a case series and review of chemotherapy options. World J Gastrointest Oncol. 2012;4:60–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dagan E. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. Genet Test. 2008;12:267–71.

    Article  CAS  PubMed  Google Scholar 

  3. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;27:433–8.

    Article  CAS  Google Scholar 

  4. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95:214–21.

    Article  CAS  PubMed  Google Scholar 

  5. Lowery M, Shah MA, Smyth E, Epstein A, Segal A, et al. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. Journal of Gastrointestinal Cancer. 2011;42:160–4.

    Article  PubMed  Google Scholar 

  6. Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biology & Therapy. 2011;12:165–8.

    Article  CAS  Google Scholar 

  7. Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.

    Article  PubMed  Google Scholar 

  8. Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000;47:945–53.

    Article  CAS  PubMed  Google Scholar 

  9. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.

    Article  CAS  PubMed  Google Scholar 

  10. Kim R, Byer J, Saif MW. BRCA and pancreatic cancer: selection of chemotherapy. JOP: Journal of the Pancreas. 2012;13:180–1.

    PubMed  Google Scholar 

  11. Tran B, Moore S, Zogopoulos GBA, Holter S, Gallinger S, Moore MJ. Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: a translational case series. J Clin Oncol. 2012;30 suppl 4:217. abstr.

    Google Scholar 

  12. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, et al. Familial pancreatic cancer: a review. Semin Oncol. 1996;23:251–75.

    CAS  PubMed  Google Scholar 

  13. Weil MK, Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011;35:7–50.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol. 2011;22 Suppl 8:72–6.

    Article  Google Scholar 

  15. Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol. 2011;7:197–211.

    Article  PubMed  Google Scholar 

  16. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.

    Article  CAS  PubMed  Google Scholar 

  17. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16:1397–402.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Minnesota, Minneapolis, MN, USA

    Nana Aburjania, Alexander M. Truskinovsky & Emil Lou

  2. MD Anderson Cancer Center, Houston, TX, USA

    Michael J. Overman

Authors
  1. Nana Aburjania
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander M. Truskinovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Overman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emil Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emil Lou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aburjania, N., Truskinovsky, A.M., Overman, M.J. et al. Ampulla of Vater Adenocarcinoma in a BRCA2 Germline Mutation Carrier. J Gastrointest Canc 45, 87–90 (2014). https://doi.org/10.1007/s12029-013-9479-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-013-9479-5

Keywords

Search

Navigation